Today, translational neuroscience faces significant challenges. Available therapies to treat brain and nervous system disorders are extremely limited and dated, and further development has effectively ceased. Disinvestment by the private sector occurred just as promising new technologies in genomics, stem cell biology, and neuroscience emerged to offer new possibilities. In this volume, experts from both academia and industry discuss how novel technologies and reworked translation concepts can create a more effective translational neuroscience. The contributors consider such topics as using genomics and neuroscience for better diagnostics and biomarker identification; new approaches to disease based on stem cell technology and more careful use of animal models; and greater attention to human biology and what it will take to make new therapies available for clinical use. They conclude with a conceptual roadmap for an effective and credible translational neuroscience -- one informed by a disease-focused knowled
MIT Press Ltd
September 18, 2015
About the author
Karoly Nikolich is Consulting Professor in the Department of Psychiatry at Stanford University Medical School as well as Founder of Circuit Therapeutics and Chairman of Alkahest, two biotechnology companies that grew out of research done at Stanford. Steven E. Hyman is Harvard University Distinguished Professor of Stem Cell and Regenerative Biology and Director of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard.